Vera Therapeutics


January 19, 2021

Vera Therapeutics Launches with $80 Million Series C Financing to Develop Phase 2b Novel Biologic for Kidney Disease

Potential first-in-class disease-modifying biologic in late-stage clinical studies Experienced executive development team from Gilead Sciences   SOUTH SAN FRANCISCO, Calif., January 19, 2021 – Vera Therapeutics, Inc., a clinical-stage biotechnology company focused on developing treatments for immunological and inflammatory diseases, today announced its launch backed by $80 million Series C financing led by Abingworth LLP.  … Read more